Clinical data | |
---|---|
Pronunciation | /bəˈnæzəprɪl/ |
Trade names | Lotensin, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a692011 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 96.7% |
Metabolism | Liver glucuronidation |
Elimination half-life | 10-11 hours |
Excretion | Kidney and bile duct |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H28N2O5 |
Molar mass | 424.497 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Benazepril, sold under the brand name Lotensin among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.[2] It is a reasonable initial treatment for high blood pressure.[2] It is taken by mouth.[2] Versions are available as the combinations benazepril/hydrochlorothiazide and benazepril/amlodipine.[2]
Common side effects include feeling tired, dizziness, cough, and light-headedness with standing.[2] Serious side effects may include kidney problems, low blood pressure, high blood potassium, and angioedema.[2] Use in pregnancy may harm the baby, while use when breastfeeding may be safe.[3] It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity.[2]
Benazepril was patented in 1981 and came into medical use in 1990. It is available as a generic medication.[2] In 2022, it was the 159th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[4][5]